ADXN
Addex Therapeutics Ltd
There isn't enough reported data to score ADXN yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ADXN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
ADXN's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ADXN PE Valuation
ADXN has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ADXN Forward outlook
There aren't enough analyst estimates for ADXN to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ADXN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$6.75 | +$2.35 |
| Q1 2026 | -$8.20 | -165% |
| Q4 2025 | -$8.92 | -188% |
| Q3 2025 | -$8.85 | -216% |
| Q2 2025 | -$9.10 | -283% |
| Q1 2025 | $12.57 | +$31.74 |
| Q4 2024 | $10.16 | +$30.43 |
| Q3 2024 | $7.61 | +$32.39 |
ADXN is still losing money, but far less than before: $6.75 per share over the past year, against $88.12 at its worst in early 2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ADXN on earnings quality, reporting a profit while its opponent remains loss making.
ADXN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.9K | -73% |
| Q4 2025 | $299 | -84% |
| Q3 2025 | $35.8K | -45% |
| Q2 2025 | $43.8K | -68% |
| Q4 2024 | $1.8K | -99% |
| Q3 2024 | $64.8K | -84% |
| Q2 2024 | $138.8K | -82% |
| Q1 2024 | $281.1K | -53% |
ADXN's revenue has slid since its 2020 peak: $11,928 last quarter, down 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -6484% | -4470 points |
| Q1 2026 | -6239% | N/A |
| Q4 2025 | -314219% | -284668 points |
| Q3 2025 | -2342% | -1186 points |
| Q2 2025 | -2015% | -1235 points |
| Q4 2024 | -29551% | -27803 points |
| Q3 2024 | -1156% | -927 points |
| Q2 2024 | -780% | -717 points |
ADXN's operating margin was −6484% last quarter, down 4470 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ADXN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ADXN on profitability, with a higher operating margin.
ADXN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$564.2K | -$58.8K |
| Q1 2026 | -$922K | -$201.2K |
| Q4 2025 | -$732.4K | -$704.1K |
| Q3 2025 | -$641.9K | -$160.5K |
| Q2 2025 | -$505.4K | +$2.8M |
| Q1 2025 | -$720.8K | +$1.9M |
| Q4 2024 | -$28.4K | +$723.1K |
| Q3 2024 | -$481.4K | +$2.2M |
ADXN has burned cash in almost every quarter: −$3M over the past year, against −$2M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ADXN on cash generation, producing positive trailing cash flow while its opponent burns cash.
ADXN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +27K shares |
| 1 year | +90% | +687K shares |
| 3 years | +142% | +852K shares |
| 5 years | +412% | +1.2M shares |
| Available history | +559% | +1.2M shares |
ADXN has 1M diluted shares, up 90% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $1,516 |
| Q1 2026 | $3,829 |
| Q4 2025 | — |
| Q3 2025 | $3,306 |
| Q2 2025 | $31,176 |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ADXN spent $8,651 buying back its own shares over the past year, down 72% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ADXN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ADXN Net Leverage
ADXN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ADXN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.0 | Neutral |
ADXN's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ADXN PE vs Healthcare Sector
| Metric | ADXN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ADXN has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ADXN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.37 | 57% above |
| 20 week MA | $4.35 | 22% above |
| 50 week MA | $5.99 | 12% below |
| 100 week MA | $7.17 | 26% below |
| 200 week MA | $9.61 | 45% below |
ADXN has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 45% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ADXN on trend strength, trading above more of its moving averages.
ADXN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $226.0 | $483.8 | +114% |
| 2021 | $483.8 | $132.6 | -73% |
| 2022 | $132.6 | $11.2 | -92% |
| 2023 | $11.2 | $6.05 | -46% |
| 2024 | $6.05 | $7.52 | +24% |
| 2025 | $7.52 | $7.99 | +6.3% |
| 2026 YTD | $7.99 | $5.29 | -34% |
ADXN's yearly returns have swung widely, from +114% in 2020 to −92% in 2022. It's down 34% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ADXN on returns for 2026, with the stronger performance.